{"nctId":"NCT02364947","briefTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)","startDateStruct":{"date":"2015-02-09","type":"ACTUAL"},"conditions":["Alcohol Dependence"],"count":678,"armGroups":[{"label":"Nalmefene hydrochloride 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Nalmefene hydrochloride"]},{"label":"Nalmefene hydrochloride 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Nalmefene hydrochloride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Nalmefene hydrochloride","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese males and females aged 20 or above who have signed the informed consent form\n* The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by Mini-international Neuropsychiatric Interview (M. I. N. I.)\n* The patient has a drinking risk level of High or above (\\> 60 g for men and \\> 40 g for women) both at the Screening Visit and at the Randomization Visit .\n\nExclusion Criteria:\n\n* The patient with a current diagnosis or history of substance use disorders (except for alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I. N. I.\n* The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12","description":"The number of HDDs is defined as the number of days per month \\[days/month\\] with alcohol consumption of \\> 60 g for males and \\> 40 g for females","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.25","spread":"0.64"},{"groupId":"OG001","value":"-12.09","spread":"0.74"},{"groupId":"OG002","value":"-7.91","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.25","spread":"0.66"},{"groupId":"OG001","value":"-13.88","spread":"0.77"},{"groupId":"OG002","value":"-9.33","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Change in Total Alcohol Consumption (TAC) From Baseline at Week 12","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.90","spread":"2.01"},{"groupId":"OG001","value":"-45.36","spread":"2.32"},{"groupId":"OG002","value":"-32.43","spread":"1.91"}]}]}]},{"type":"SECONDARY","title":"Change in Total Alcohol Consumption (TAC) From Baseline at Week 24","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.43","spread":"2.13"},{"groupId":"OG001","value":"-49.55","spread":"2.45"},{"groupId":"OG002","value":"-38.28","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Response Shift Drinking Risk Level (RSDRL) at Week 12","description":"Proportion of patients with a downward shift in drinking risk level of two categories or more","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"35.7","spread":null},{"groupId":"OG002","value":"20.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Shift Drinking Risk Level (RSDRL) at Week 24","description":"Proportion of patients with a downward shift in drinking risk level of two categories or more","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Low Drinking Risk Level (RLDRL) at Week 12","description":"Proportion of patients with low or lower drinking risk level","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"25.3","spread":null},{"groupId":"OG002","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Low Drinking Risk Level (RLDRL) at Week 24","description":"Proportion of patients with low or lower drinking risk level","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"32.6","spread":null},{"groupId":"OG002","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"70% TAC Responder Rate at Week 12","description":"Proportion of patients with a 70% decrease in TAC","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"19.5","spread":null},{"groupId":"OG002","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"70% TAC Responder Rate at Week 24","description":"Proportion of patients with a 70% decrease in TAC","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"HDD Responder Rate at Week 12","description":"Proportion of patients with ≤4 HDDs","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"HDD Responder Rate at Week 24","description":"Proportion of patients with ≤4 HDDs","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"44.0","spread":null},{"groupId":"OG002","value":"25.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CGI-S From Baseline at Week 12","description":"The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.05"},{"groupId":"OG001","value":"-0.63","spread":"0.06"},{"groupId":"OG002","value":"-0.34","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in CGI-S From Baseline at Week 24","description":"The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"0.06"},{"groupId":"OG001","value":"-0.77","spread":"0.07"},{"groupId":"OG002","value":"-0.41","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in CGI-I From Baseline at Week 12","description":"The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"0.07"},{"groupId":"OG001","value":"2.65","spread":"0.08"},{"groupId":"OG002","value":"3.13","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in CGI-I From Baseline at Week 24","description":"The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.07"},{"groupId":"OG001","value":"2.44","spread":"0.09"},{"groupId":"OG002","value":"2.99","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12","description":"All-patients-randomised set","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.666","spread":"0.027"},{"groupId":"OG001","value":"3.702","spread":"0.031"},{"groupId":"OG002","value":"3.858","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24","description":"All-patients-randomised set","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.663","spread":"0.031"},{"groupId":"OG001","value":"3.692","spread":"0.035"},{"groupId":"OG002","value":"3.831","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12","description":"All-patients-randomised set","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.968","spread":"0.023"},{"groupId":"OG001","value":"2.988","spread":"0.027"},{"groupId":"OG002","value":"3.038","spread":"0.021"}]}]}]},{"type":"SECONDARY","title":"Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24","description":"All-patients-randomised set","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.971","spread":"0.023"},{"groupId":"OG001","value":"2.987","spread":"0.027"},{"groupId":"OG002","value":"3.036","spread":"0.021"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":248},"commonTop":["Nasopharyngitis","Nausea","Dizziness","Somnolence","Headache"]}}}